Bentley Pharmaceuticals Receives Approval to Market Product in Russia.TAMPA, Fla.--(BUSINESS WIRE)--May 28, 1997--Bentley Pharmaceuticals, Inc. (AMEX AMEX See: American Stock Exchange :BNT BNT Bentley Pharmaceuticals, Inc. (stock symbol) BNT Boston Naming Test (psychology) BNT Bermuda National Trust BNT Bulgarian National TV BNT Broadband Network Termination BNT Binary File Transfer ) today reported that the Ministry of Health of the Russian Federation has granted registration to Bentley's Spanish subsidiary, for the 5mg and 20mg dosage forms of its product Controlvas. Sales are expected to commence during the third quarter of 1997. Controlvas, which is a cardiovascular drug used to treat hypertension and congestive heart failure congestive heart failure, inability of the heart to expel sufficient blood to keep pace with the metabolic demands of the body. In the healthy individual the heart can tolerate large increases of workload for a considerable length of time. , is one of Bentley's leading products with annual sales in 1996 of approximately $1.5 million. "This venture represents the initial entry into an exciting new marketplace for Bentley," said James R. Murphy, chairman and chief executive officer of Bentley Pharmaceuticals. "Bentley enters this market with the intention of establishing marketing and promotional agreements with pharmaceutical distribution companies in Russia," added Murphy. By leveraging competitive advantages of relatively low-cost GMP GMP (guanosine monophosphate): see guanine. accredited accredited recognition by an appropriate authority that the performance of a particular institution has satisfied a prestated set of criteria. accredited herds cattle herds which have achieved a low level of reactors to, e.g. manufacturing capability, novel drug-delivery technologies and an international sales and marketing presence, Tampa-based Bentley Pharmaceuticals, Inc. is an emerging international pharmaceutical company with a broad and expanding line of off-patent drugs off-patent drugs see generic (2). marketed in Spain that prevent or treat illnesses in the following therapeutic categories: cardiovascular, gastrointestinal, neurological and infectious diseases. Safe Harbor Statement under the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995 - The statements which are not historical facts contained in this press release are forward-looking statements that involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, regulatory approval processes, the impact of competitive products or pricing, unpredictability of patent protection, technological changes, the effect of economic conditions and other uncertainties detailed in the company's filings with the Securities and Exchange Commission. CONTACT: L.B. Stauffer Thomas D. Gibson, Media Porter, Le Vay & Rose, Inc. Consultant (212) 564-4700 or Michael D. Price, Chief Financial Officer (813) 286-4401 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion